Compass Therapeutics (CMPX) Competitors

$1.81 -0.02 (-1.09%)

Closing price 04:00 PM Eastern

Extended Trading

$1.80 -0.01 (-0.28%)

As of 07:56 PM Eastern

CMPX vs. CRVS, OLMA, MAZE, CMPS, and JBIO

Should you buy Compass Therapeutics stock or one of its competitors? MarketBeat compares Compass Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Compass Therapeutics include Corvus Pharmaceuticals (CRVS), Olema Pharmaceuticals (OLMA), Maze Therapeutics (MAZE), Compass Pathways (CMPS), and Jade Biosciences (JBIO). These companies are all part of the "pharmaceutical products" industry.

How does Compass Therapeutics compare to Corvus Pharmaceuticals?

Compass Therapeutics (NASDAQ:CMPX) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

In the previous week, Corvus Pharmaceuticals had 15 more articles in the media than Compass Therapeutics. MarketBeat recorded 19 mentions for Corvus Pharmaceuticals and 4 mentions for Compass Therapeutics. Corvus Pharmaceuticals' average media sentiment score of -0.07 beat Compass Therapeutics' score of -0.13 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corvus Pharmaceuticals has lower revenue, but higher earnings than Compass Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	383.49	-$66.49M	-$0.41	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Compass Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Corvus Pharmaceuticals' return on equity of -38.92% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-39.75%	-35.29%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

Compass Therapeutics presently has a consensus price target of $13.60, suggesting a potential upside of 651.38%. Corvus Pharmaceuticals has a consensus price target of $33.33, suggesting a potential upside of 189.86%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Compass Therapeutics beats Corvus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Compass Therapeutics compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Compass Therapeutics' return on equity of -39.75% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Compass Therapeutics	N/A	-39.75%	-35.29%

Compass Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Compass Therapeutics	$850K	383.49	-$66.49M	-$0.41	N/A

In the previous week, Olema Pharmaceuticals had 6 more articles in the media than Compass Therapeutics. MarketBeat recorded 10 mentions for Olema Pharmaceuticals and 4 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of -0.13 beat Olema Pharmaceuticals' score of -0.58 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative
Compass Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Olema Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Olema Pharmaceuticals currently has a consensus target price of $44.10, suggesting a potential upside of 236.64%. Compass Therapeutics has a consensus target price of $13.60, suggesting a potential upside of 651.38%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than Olema Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Compass Therapeutics beats Olema Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Compass Therapeutics compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Compass Therapeutics has lower revenue, but higher earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	8.08	-$131.12M	-$2.53	N/A
Compass Therapeutics	$850K	383.49	-$66.49M	-$0.41	N/A

In the previous week, Maze Therapeutics had 13 more articles in the media than Compass Therapeutics. MarketBeat recorded 17 mentions for Maze Therapeutics and 4 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of -0.13 beat Maze Therapeutics' score of -0.49 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maze Therapeutics has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

68.4% of Compass Therapeutics shares are held by institutional investors. 5.3% of Maze Therapeutics shares are held by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Maze Therapeutics' return on equity of -36.62% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
Compass Therapeutics	N/A	-39.75%	-35.29%

Maze Therapeutics presently has a consensus price target of $66.00, suggesting a potential upside of 169.83%. Compass Therapeutics has a consensus price target of $13.60, suggesting a potential upside of 651.38%. Given Compass Therapeutics' higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Compass Therapeutics beats Maze Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Compass Therapeutics compare to Compass Pathways?

Compass Therapeutics (NASDAQ:CMPX) and Compass Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by insiders. Comparatively, 2.8% of Compass Pathways shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Compass Therapeutics currently has a consensus target price of $13.60, indicating a potential upside of 651.38%. Compass Pathways has a consensus target price of $20.58, indicating a potential upside of 104.40%. Given Compass Therapeutics' higher probable upside, equities research analysts clearly believe Compass Therapeutics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

Compass Therapeutics has higher revenue and earnings than Compass Pathways. Compass Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	383.49	-$66.49M	-$0.41	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

Compass Pathways' return on equity of -31.07% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-39.75%	-35.29%
Compass Pathways	N/A	-31.07%	-11.40%

Compass Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.39, suggesting that its stock price is 139% more volatile than the broader market.

In the previous week, Compass Pathways had 33 more articles in the media than Compass Therapeutics. MarketBeat recorded 37 mentions for Compass Pathways and 4 mentions for Compass Therapeutics. Compass Pathways' average media sentiment score of 0.73 beat Compass Therapeutics' score of -0.13 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Pathways	6 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compass Pathways beats Compass Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Compass Therapeutics compare to Jade Biosciences?

Compass Therapeutics (NASDAQ:CMPX) and Jade Biosciences (NASDAQ:JBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Compass Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

Compass Therapeutics presently has a consensus price target of $13.60, indicating a potential upside of 651.38%. Jade Biosciences has a consensus price target of $34.33, indicating a potential upside of 56.92%. Given Compass Therapeutics' higher probable upside, equities research analysts clearly believe Compass Therapeutics is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

In the previous week, Jade Biosciences had 4 more articles in the media than Compass Therapeutics. MarketBeat recorded 8 mentions for Jade Biosciences and 4 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of -0.13 beat Jade Biosciences' score of -0.76 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Compass Therapeutics	Neutral
Jade Biosciences	Negative

Compass Therapeutics has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	383.49	-$66.49M	-$0.41	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Compass Therapeutics' return on equity of -39.75% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-39.75%	-35.29%
Jade Biosciences	N/A	-51.34%	-47.32%

68.4% of Compass Therapeutics shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by company insiders. Comparatively, 23.1% of Jade Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Compass Therapeutics beats Jade Biosciences on 10 of the 15 factors compared between the two stocks.

Get Compass Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMPX vs. The Competition

Export

Metric	Compass Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$329.56M	$3.25B	$6.25B	$12.23B
Dividend Yield	N/A	2.34%	2.80%	5.27%
P/E Ratio	-4.41	18.52	20.79	25.04
Price / Sales	383.49	270.32	531.21	72.17
Price / Cash	N/A	124.58	43.09	54.25
Price / Book	1.74	6.60	9.81	6.83
Net Income	-$66.49M	$24.18M	$3.55B	$335.69M
7 Day Performance	-3.21%	-3.56%	-2.07%	-2.03%
1 Month Performance	-69.83%	-7.86%	-3.90%	-1.90%
1 Year Performance	-14.22%	51.80%	29.39%	27.36%

Compass Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMPX Compass Therapeutics	2.9131 of 5 stars	$1.81 -1.1%	$13.60 +651.4%	-12.9%	$329.56M	$850K	N/A	20
CRVS Corvus Pharmaceuticals	2.0687 of 5 stars	$15.81 +1.7%	$33.33 +110.8%	+238.2%	$1.31B	N/A	N/A	30	Trending News Analyst Revision Gap Up
OLMA Olema Pharmaceuticals	1.998 of 5 stars	$14.86 -0.3%	$44.40 +198.8%	+173.9%	$1.30B	N/A	N/A	70	Earnings Report
MAZE Maze Therapeutics	2.0995 of 5 stars	$25.52 -2.0%	$66.00 +158.6%	+164.9%	$1.30B	N/A	N/A	121	Trending News Earnings Report Analyst Upgrade Insider Trade Analyst Revision
CMPS Compass Pathways	3.7622 of 5 stars	$9.65 -2.6%	$20.55 +112.9%	+165.3%	$1.28B	N/A	N/A	120	Trending News Earnings Report Analyst Upgrade Options Volume Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMPX) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compass Therapeutics (CMPX) Competitors

CMPX vs. CRVS, OLMA, MAZE, CMPS, and JBIO

How does Compass Therapeutics compare to Corvus Pharmaceuticals?

Summary

How does Compass Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Compass Therapeutics compare to Maze Therapeutics?

Summary

How does Compass Therapeutics compare to Compass Pathways?

Summary

How does Compass Therapeutics compare to Jade Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX vs. The Competition

Compass Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compass Therapeutics (CMPX) Competitors

CMPX vs. CRVS, OLMA, MAZE, CMPS, and JBIO

How does Compass Therapeutics compare to Corvus Pharmaceuticals?

Does the media refer more to CMPX or CRVS?

Which has preferable earnings & valuation, CMPX or CRVS?

Which has more volatility and risk, CMPX or CRVS?

Is CMPX or CRVS more profitable?

Do analysts recommend CMPX or CRVS?

Do insiders & institutionals have more ownership in CMPX or CRVS?

Summary

How does Compass Therapeutics compare to Olema Pharmaceuticals?

Do institutionals and insiders hold more shares of OLMA or CMPX?

Is OLMA or CMPX more profitable?

Which has preferable earnings & valuation, OLMA or CMPX?

Does the media favor OLMA or CMPX?

Which has more risk and volatility, OLMA or CMPX?

Do analysts rate OLMA or CMPX?

Summary

How does Compass Therapeutics compare to Maze Therapeutics?

Which has stronger valuation & earnings, MAZE or CMPX?

Does the media refer more to MAZE or CMPX?

Which has more risk & volatility, MAZE or CMPX?

Do institutionals & insiders hold more shares of MAZE or CMPX?

Is MAZE or CMPX more profitable?

Do analysts rate MAZE or CMPX?

Summary

How does Compass Therapeutics compare to Compass Pathways?

Do insiders & institutionals believe in CMPX or CMPS?

Do analysts recommend CMPX or CMPS?

Which has higher valuation & earnings, CMPX or CMPS?

Is CMPX or CMPS more profitable?

Which has more volatility and risk, CMPX or CMPS?

Does the media prefer CMPX or CMPS?

Summary

How does Compass Therapeutics compare to Jade Biosciences?

Which has more risk and volatility, CMPX or JBIO?

Do analysts rate CMPX or JBIO?

Does the media refer more to CMPX or JBIO?

Which has higher valuation and earnings, CMPX or JBIO?

Is CMPX or JBIO more profitable?

Do insiders and institutionals hold more shares of CMPX or JBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX vs. The Competition

Compass Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools